drugset / Trial / NCT06369259
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
Timeline
- Start
- 2025-02-24
- Primary completion
- 2029-02-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | — | Oral |
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Defactinib | Small molecule | — | Oral |